Stocksigma LogoStocksigma Logo

Shree Ganesh Remedies Reports Weak Q2FY27 Results Amid Input Cost Pressures

Shree Ganesh Remedies reported a challenging Q2FY27, with revenue declining 23% YoY to ₹23.29 Cr, EBITDA dropping 59% YoY to ₹3.94 Cr, and PAT falling 67%

Shree Ganesh Remedies Reports Weak Q2FY27 Results Amid Input Cost Pressures

Shree Ganesh Remedies Ltd · Press Release · 02 Nov 2026, 12:37 am

Shree Ganesh Remedies Reports Weak Q2FY27 Results Amid Input Cost Pressures Shree Ganesh Remedies reported a challenging Q2FY27, with revenue declining 23% YoY to ₹23.29 Cr, EBITDA dropping 59% YoY to ₹3.94 Cr, and PAT falling 67% YoY to ₹1.63 Cr. EBITDA margins contracted 1,483 bps YoY to 16.9%, impacted by volatile raw material costs and subdued European demand. However, performance rebounded QoQ, with revenue rising 62% and PAT gaining 46%. H1FY27 revenue and PAT stood at ₹37.65 Cr and ₹2.75 Cr, down 32% and 67% YoY, respectively. Construction of Block 7A is completed to support its expanding CRAMS pipeline.

Original exchange filing (PDF)

More announcements from Shree Ganesh Remedies Ltd

All Shree Ganesh Remedies Ltd announcements